[Home](https://github.com/mm80843/T3.5/blob/main/docs/index.md) >> Class: [Risk](https://github.com/mm80843/T3.5/tree/main/docs/Risk/index.md) >> Individual ID:PBN__Risk_1540 

# __Lack of vaccines and agent-specific drugs__

## Category to which it belongs

* [The challenges in vaccination include limited storage capacity, high patient demand, inefficient resource use, distribution difficulties, waning vaccine effectiveness, and unequal access.](https://github.com/mm80843/T3.5/blob/main/docs/PBNCategory/PBN__PBNCategory_113.md)

## Closest similar item

* [Lack of drugs and vaccines](https://github.com/mm80843/T3.5/blob/main/docs/Risk/PBN__Risk_1349.md)
* [Lack of vaccine or cure](https://github.com/mm80843/T3.5/blob/main/docs/Risk/PBN__Risk_1748.md)
* [Lack of medication and vaccines for COVID-19](https://github.com/mm80843/T3.5/blob/main/docs/Risk/PBN__Risk_1495.md)
* [Lack of knowledge about the virus, treatments, and vaccines](https://github.com/mm80843/T3.5/blob/main/docs/Risk/PBN__Risk_2920.md)
* [Lack of COVID-19 vaccine](https://github.com/mm80843/T3.5/blob/main/docs/Risk/PBN__Risk_2303.md)
* [Lack of preexisting immunities](https://github.com/mm80843/T3.5/blob/main/docs/Risk/PBN__Risk_2109.md)
* [Vaccine availability, Vaccine hesitancy](https://github.com/mm80843/T3.5/blob/main/docs/Risk/PBN__Risk_3168.md)
* [Demand for vaccine development](https://github.com/mm80843/T3.5/blob/main/docs/Risk/PBN__Risk_423.md)
* [Inadequate vaccine efficacy](https://github.com/mm80843/T3.5/blob/main/docs/Risk/PBN__Risk_1911.md)
* [Lack of immunity](https://github.com/mm80843/T3.5/blob/main/docs/Risk/PBN__Risk_2771.md)

## Description of the risk

Inadequacy of vaccines and agent-specific drugs for respiratory viruses.

## Property: has_RiskGBN

* [No](https://github.com/mm80843/T3.5/blob/main/docs/RiskGBN/PBN__RiskGBN_0.md)

## Property: has_RiskHealth

* [physical](https://github.com/mm80843/T3.5/blob/main/docs/RiskHealth/PBN__RiskHealth_0.md)

## Property: has_RiskISO_Impact

* [Biodiversity and ecosystem services](https://github.com/mm80843/T3.5/blob/main/docs/RiskISO/PBN__RiskISO_Purpose_4.md)

## Property: has_RiskISO_Purpose

* [Attractiveness](https://github.com/mm80843/T3.5/blob/main/docs/RiskISO/PBN__RiskISO_Impact_9.md)

## Mitigations of this risk

* [Investment in research and development for vaccines and agent-specific drugs.](https://github.com/mm80843/T3.5/blob/main/docs/RiskMitigation/PBN__RiskMitigation_2069.md)

## Name of the risk

Limited prevention and treatment options during viral epidemics.

## Stakeholders who can mitigate this risk

* [pharmaceutical companies](https://github.com/mm80843/T3.5/blob/main/docs/Stakeholder/PBN__Stakeholder_124.md)
* [government research institutions](https://github.com/mm80843/T3.5/blob/main/docs/Stakeholder/PBN__Stakeholder_994.md)

## Articles mentionning the risk

* [Physical interventions to interrupt or reduce the spread of respiratory viruses: systematic review](https://github.com/mm80843/T3.5/blob/main/docs/Article/PBN__Article_22.md)

## People affected by this risk

* [healthcare workers](https://github.com/mm80843/T3.5/blob/main/docs/Stakeholder/PBN__Stakeholder_68.md)
* [general population](https://github.com/mm80843/T3.5/blob/main/docs/Stakeholder/PBN__Stakeholder_9.md)

## Technologies linked to the risk

* [vaccine development](https://github.com/mm80843/T3.5/blob/main/docs/Technology/PBN__Technology_837.md)
* [antiviral drug research](https://github.com/mm80843/T3.5/blob/main/docs/Technology/PBN__Technology_838.md)

## Property: has_RiskType

* [technological](https://github.com/mm80843/T3.5/blob/main/docs/RiskType/PBN__RiskType_5.md)

